Stolbach L L, Begg C B, Hall T, Horton J
Cancer Treat Rep. 1981 Jul-Aug;65(7-8):689-92.
Seventy patients with metastatic renal carcinoma were randomized to receive hydroxyurea, nafoxidine, or medroxyprogesterone (Provera) orally. Sixty patients were considered evaluable, with a response rate of 5% for medroxyprogesterone (one complete remission) and hydroxyurea (one partial remission) and a response rate of 16% for nafoxidine (two complete remissions and one partial remission). Differences in response rates and duration of survival were not statistically significant. The major toxicity observed with hydroxyurea was hematologic, and the major toxic effect of nafoxidine was an ichthyosis-like skin rash. Toxicity for medroxyprogesterone was minimal.
70例转移性肾癌患者被随机分为口服羟基脲、萘福昔定或甲羟孕酮（安宫黄体酮）三组。60例患者可进行评估，甲羟孕酮（1例完全缓解）和羟基脲（1例部分缓解）的缓解率为5%，萘福昔定的缓解率为16%（2例完全缓解和1例部分缓解）。缓解率和生存期的差异无统计学意义。羟基脲观察到的主要毒性是血液学毒性，萘福昔定的主要毒性作用是鱼鳞病样皮疹。甲羟孕酮的毒性最小。
